Ret transgenic mouse model of spontaneous skin melanoma: Focus on regulatory T cells

Pigment Cell and Melanoma Research

Volumn 26, Issue 4, 2013, Pages 457-463

  Umansky, Viktor ^a,b   Sevko, Alexandra ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Immunosuppression; Melanoma; Memory T cells; Regulatory T cells; Transgenic mouse model; Tumor microenvironment

Indexed keywords

MELANOMA ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW METASTASIS; BRAIN METASTASIS; CANCER CELL; CANCER GROWTH; CANCER MODEL; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; GENE OVEREXPRESSION; LEUKOCYTE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; ONCOGENE RET; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; INFLAMMATION; LEUKOCYTES; MELANOMA; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-RET; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSGENES;

MUS MUSCULUS;

EID: 84879785030     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12104     Document Type: Article

References (82)

1. Abschuetz, O., Osen, W., Frank, K., Kato, M., Schadendorf, D., Baniyash, M., and Umansky, V. (2012). T-cell mediated immune responses induced in ret transgenic mouse model of malignant melanoma. Cancers 4, 490-503.
2. Aguirre-Ghiso, J.A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 11, 834-846.
3. Alderson, K.L., and Murphy, W.J. (2010). Antigen specific memory T cells and their putative need for the generation of sustained anti-tumor responses. Adv. Exp. Med. Biol. 684, 155-165.
4. Antony, P.A., Piccirillo, C.A., Akpinarli, A. et al. (2005). CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601.
5. Attia, P., Maker, A.V., Haworth, L.R., Rogers-Freezer, L., and Rosenberg, S.A. (2005). Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28, 582-592.
6. Becker, T.C., Coley, S.M., Wherry, E.J., and Ahmed, R. (2005). Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J. Immunol. 174, 1269-1273.
7. Becker, J.C., Houben, R., Schrama, D., Voigt, H., Ugurel, S., and Reisfeld, R.A. (2010). Mouse models for melanoma: a personal perspective. Exp. Dermatol. 19, 157-164.
8. Beckhove, P., Feuerer, M., Dolenc, M. et al. (2004). Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clin. Invest. 114, 67-76.
9. Ben-Neriah, Y., and Karin, M. (2011). Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 12, 715-723.
10. Beyer, M., and Schultze, J.L. (2006). Regulatory T cells in cancer. Blood 108, 804-811.
11. Boon, T., Coulie, P.G., Van den Eynde, B.J., and van der Bruggen, P. (2006). Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208.
12. Camus, M., and Galon, J. (2010). Memory T-cell responses and survival in human cancer: remember to stay alive. Adv. Exp. Med. Biol. 684, 166-177.
13. Cipponi, A., Wieers, G., van Baren, N., and Coulie, P.G. (2011). Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol. Immunother. 60, 1153-1160.
14. Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S., and Vignali, D.A. (2007). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 50, 566-569.
15. De Palma, M., Murdoch, C., Venneri, M.A., Naldini, L., and Lewis, C.E. (2007). Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 28, 519-524.
16. Di Rosa, F., and Pabst, R. (2005). The bone marrow: a nest for migratory memory T cells. Trends Immunol. 26, 360-366.
17. Eng, C. (1999). RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17, 380-383.
18. Ferrone, S., and Marincola, F.M. (1995). Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494.
19. Feuerer, M., Beckhove, P., Bai, L., Solomayer, E.F., Bastert, G., Diehl, I.J., Pedain, C., Oberniedermayr, M., Schirrmacher, V., and Umansky, V. (2001). Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow. Nat. Med. 7, 452-458.
20. Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., and Rivoltini, L. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553.
21. Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G.S., and Albelda, S.M. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16, 183-194.
22. Fu, S., Zhang, N., Yopp, A.C., Chen, D., Mao, M., Chen, D., Zhang, H., Ding, Y., and Bromberg, J.S. (2004). TGF-beta induces Foxp3+ T-regulatory cells from CD4+ CD25 - precursors. Am. J. Transplant. 4, 1614-1627.
23. Gabrilovich, D.I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268.
24. Gajewski, T.F. (2007). Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13, 5256-5261.
25. Garbe, C., Peris, K., Hauschild, A. et al. (2010). Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur. J. Cancer 46, 270-283.
26. Grauer, O.M., Sutmuller, R.P., van Maren, W., Jacobs, J.F., Bennink, E., Toonen, L.W., Nierkens, S., and Adema, G.J. (2008). Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int. J. Cancer 122, 1794-1802.
27. Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
28. Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061.
29. Houghton, A., and Polsky, D. (2002). Focus on melanoma. Cancer Cell 2, 275-278.
30. Iellem, A., Mariani, M., Lang, R., Recalde, H., Panina-Bordignon, P., Sinigaglia, F., and D'Ambrosio, D. (2001). Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194, 847-853.
31. Imai, H., Saio, M., Nonaka, K. et al. (2007). Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. 98, 416-423.
32. Jandus, C., Speiser, D., and Romero, P. (2009). Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res. 22, 711-723.
33. Jones, E., Dahm-Vicker, M., Simon, A.K., Green, A., Powrie, F., Cerundolo, V., and Gallimore, A. (2002). Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2, 1.
34. Jordan, J.T., Sun, W., Hussain, S.F., DeAngulo, G., Prabhu, S.S., and Heimberger, A.B. (2008). Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 57, 123-131.
35. Josefowicz, S.Z., Lu, L.F., and Rudensky, A.Y. (2012). Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564.
36. Kato, M., Takahashi, M., Akhand, A.A., Liu, W., Dai, Y., Shimizu, S., Iwamoto, T., Suzuki, H., and Nakashima, I. (1998). Transgenic mouse model for skin malignant melanoma. Oncogene 17, 1885-1888.
37. Kianizad, K., Marshall, L.A., Grinshtein, N., Bernard, D., Margl, R., Cheng, S., Beermann, F., Wan, Y., and Bramson, J. (2007). Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res. 67, 6459-6467.
38. Kimpfler, S., Sevko, A., Ring, S., Falk, C., Osen, W., Frank, K., Kato, M., Mahnke, K., Schadendorf, D., and Umansky, V. (2009). Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J. Immunol. 183, 6330-6337.
39. Kusmartsev, S., and Gabrilovich, D.I. (2006). Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 25, 323-331.
40. Kwong, L.N., Costello, J.C., Liu, H. et al. (2012). Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 18, 1503-1510.
41. Lefrançois, L. (2006). Development, trafficking, and function of memory T-cell subsets. Immunol. Rev. 211, 93-103.
42. Lengagne, R., Le Gal, F.A., Garcette, M. et al. (2004). Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res. 15, 1496-1501.
43. Lengagne, R., Graff-Dubois, S., Garcette, M., Renia, L., Kato, M., Guillet, J.G., Engelhard, V.H., Avril, M.F., Abastado, J.P., and Prévost-Blondel, A. (2008). Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J. Immunol. 180, 130-137.
44. Lengagne, R., Pommier, A., Caron, J. et al. (2011). T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma. PLoS One 6, e20235.
45. Letsch, A., Keilholz, U., Assfalg, G., Mailander, V., Thiel, E., and Scheibenbogen, C. (2003). Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Res. 63, 5582-5586.
46. MacKie, R.M., Hauschild, A., and Eggermont, A.M. (2009). Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 20(suppl 6), vi1-vi7.
47. Mahnke, K., Bedke, T., and Enk, A.H. (2007a). Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell. Immunol. 250, 1-13.
48. Mahnke, K., Schonfeld, K., Fondel, S. et al. (2007b). Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120, 2723-2733.
49. McKinney, A.J., and Holmen, S.L. (2011). Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin. J. Cancer 30, 153-162.
50. Meyer, C., Sevko, A., Ramacher, M. et al. (2011). Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl Acad. Sci. USA 108, 17111-17116.
51. Muller-Berghaus, J., Ehlert, K., Ugurel, S., Umansky, V., Bucur, M., Schirrmacher, V., Beckhove, P., and Schadendorf, D. (2006). Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res. 66, 5997-6001.
52. Nishikawa, H., and Sakaguchi, S. (2010). Regulatory T cells in tumor immunity. Int. J. Cancer 127, 759-767.
53. Oderup, C., Cederbom, L., Makowska, A., Cilio, C.M., and Ivars, F. (2006). Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 118, 240-249.
54. Ostrand-Rosenberg, S. (2008). Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 18, 11-18.
55. Parmiani, G., Castelli, C., Santinami, M., and Rivoltini, L. (2007). Melanoma immunology: past, present and future. Curr. Opin. Oncol. 19, 121-127.
56. Piccirillo, C.A., and Shevach, E.M. (2004). Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16, 81-88.
57. Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G.V., and Kiessling, R. (2010). Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70, 4335-4345.
58. Ramirez-Montagut, T., Turk, M.J., Wolchok, J.D., Guevara-Patino, J.A., and Houghton, A.N. (2003). Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22, 3180-3187.
59. Ren, X., Ye, F., Jiang, Z., Chu, Y., Xiong, S., and Wang, Y. (2007). Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ. 14, 2076-2084.
60. Rivoltini, L., Canese, P., Huber, V. et al. (2005). Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. Expert Opin. Biol. Ther. 5, 463-476.
61. Rudensky, A.Y. (2011). Regulatory T cells and Foxp3. Immunol. Rev. 241, 260-268.
62. Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345-352.
63. Sallusto, F., Geginat, J., and Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763.
64. Sauer, A.V., Brigida, I., Carriglio, N. et al. (2011). Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 119, 1428-1439.
65. Savage, P.A., Malchow, S., and Leventhal, D.S. (2013). Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 34, 33-40.
66. Sebastiani, S., Allavena, P., Albanesi, C., Nasorri, F., Bianchi, G., Traidl, C., Sozzani, S., Girolomoni, G., and Cavani, A. (2001). Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J. Immunol. 166, 996-1002.
67. Seliger, B. (2012). Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol. Immunother. 61, 249-254.
68. Shevach, E.M. (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30, 636-645.
69. Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999). Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218.
70. Shurin, M.R., Naiditch, H., Zhong, H., and Shurin, G.V. (2011). Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol. Ther. 11, 988-992.
71. Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M.G., Rimoldi, M., Biswas, S.K., Allavena, P., and Mantovani, A. (2008). Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349-355.
72. Smalley, K.S. (2010). Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 130, 28-37.
73. Umansky, V., Abschuetz, O., Osen, W., Ramacher, M., Zhao, F., Kato, M., and Schadendorf, D. (2008). Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res. 68, 9451-9458.
74. Vignali, D.A., Collison, L.W., and Workman, C.J. (2008). How regulatory T cells work. Nat. Rev. Immunol. 8, 523-532.
75. Webster, W.S., Thompson, R.H., Harris, K.J., Frigola, X., Kuntz, S., Inman, B.A., and Dong, H. (2007). Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 179, 2860-2869.
76. Wei, S., Kryczek, I., and Zou, W. (2006). Regulatory T-cell compartmentalization and trafficking. Blood 108, 426-431.
77. Whiteside, T.L. (2012). What are regulatory T cells (Treg) regulating in cancer and why? Semin. Cancer Biol. 22, 327-334.
78. Wood, A.H., Zhang, X., Farber, D.L., and Strome, S.E. (2007). CD8+ memory T lymphocytes from bone marrow - immune function and therapeutic potential. Crit. Rev. Immunol. 27, 527-537.
79. Zhang, X., Dong, H., Lin, W. et al. (2006). Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. J. Immunol. 177, 6730-6737.
80. Zhao, F., Falk, C., Osen, W., Kato, M., Schadendorf, D., and Umansky, V. (2009). Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin. Cancer Res. 15, 4382-4390.
81. Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274.
82. Zou, L., Barnett, B., Safah, H., Larussa, V.F., Evdemon-Hogan, M., Mottram, P., Wei, S., David, O., Curiel, T.J., and Zou, W. (2004). Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 64, 8451-8455.